Novozymes and Novo Nordisk Pharmatech partner to develop advanced technical enzymes to support biopharmaceutical production processes.
Novozymes and Novo Nordisk Pharmatech have formed a collaboration to develop specialized enzymes for use in biopharmaceutical treatment and regenerative drugs, with a focus on stem cells and gene therapies. The companies expect to have an initial product on the market within a few years, they announced in a press release on November 25, 2021.
Novozymes brings a great diversity of enzymes, a large portfolio of enzymes, a large enzymatic R&D platform and strong fermentation capabilities to the collaboration. For its part, Novo Nordisk Pharmatech recently invested in an enzyme purification plant for high quality biopharmaceutical production.
Specialty enzymes are in high demand in the biopharmaceutical industry, driven by the production of proteins and cells, according to the company’s press release. Older production technologies are increasingly being replaced by enzyme alternatives, especially in the area of regenerative drugs, which require high quality pharmaceutical grade enzymes.
“I am very excited about this collaboration, where synergies between the companies of the Novo group will come into play and with the prospect of enabling the intensification of processes in the regenerative drugs market,” said Ulla Grove Krogsgaard Thomsen, CEO of Novo Nordisk. Pharmatech, in the press release.
Source: Novo Nordisk Pharmatech